This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| flavagline | |
|---|---|
| Name | Flavagline |
| Caption | Representative structure of a flavagline natural product (rocaglamide) |
| Othernames | Rocaglamide class compounds |
flavagline
Flavaglines are a class of natural products originally isolated from plants of the genera Aglaia and Meliaceae that attracted attention for their potent antineoplastic and antiviral activities. First reported in studies involving Southeast Asian ethnobotany and natural product chemistry, these compounds have been investigated by researchers at institutions such as National Institutes of Health, Institut Pasteur, and universities including Harvard University and University of Tokyo. Early work by teams associated with University of Illinois and Max Planck Society helped define their core scaffold and bioactivity spectrum.
Flavaglines comprise a family of cyclopenta[b]benzofuran natural products typified by lead molecules like rocaglamide and silvestrol, discovered in Aglaia silvestris and related species. Interest from laboratories at MIT, Stanford University, University of Oxford, and pharmaceutical groups including Pfizer and Novartis has focused on their unique modes of action against malignancies studied in models developed at Fred Hutchinson Cancer Center and MD Anderson Cancer Center. Collaborative projects involving World Health Organization initiatives and non‑profit partners such as Wellcome Trust have explored their antiviral potential against pathogens studied at Centers for Disease Control and Prevention and European Centre for Disease Prevention and Control.
Structurally, flavaglines feature a cyclopenta[b]benzofuran core bearing multiple stereocenters and varying substituents such as methoxy, benzoyl, and amide groups; representative members include rocaglamide, silvestrol, and more polar analogs characterized in work at Scripps Research Institute and Rothamsted Research. Classification schemes used by chemists at IUPAC and analytical groups at American Chemical Society meetings categorize flavaglines within the broader flavonoid‑related natural product families described in textbooks from Oxford University Press and Springer Nature. High‑resolution studies using techniques developed at National Institute of Standards and Technology and instrumentation from Bruker and Agilent Technologies established stereochemistry assignments.
Primary sources of flavaglines are species in the genus Aglaia, native to regions including Southeast Asia, Papua New Guinea, and Queensland; botanists at Kew Gardens and herbariums at Smithsonian Institution have cataloged collections. Biosynthetic investigations by teams at University of California, Berkeley and Kyoto University indicate origins from the shikimate and mevalonate pathways, with proposed enzyme classes including cytochrome P450s and prenyltransferases analogous to enzymes characterized at ETH Zurich and Max Planck Institute for Chemical Ecology. Metabolomic profiling efforts supported by European Molecular Biology Laboratory and Cold Spring Harbor Laboratory have mapped candidate gene clusters.
Flavaglines exhibit pronounced cytotoxicity against cell lines used in research at American Cancer Society and translational centers such as Dana‑Farber Cancer Institute, with activity profiles reported against leukemia, lymphoma, and solid tumor models studied at Johns Hopkins University and Imperial College London. Mechanistically, work from groups at Rockefeller University and Yale School of Medicine implicates modulation of translation initiation factors, interaction with eukaryotic initiation factor complexes studied by researchers at EMBL‑EBI, and disruption of Ras‑dependent signaling pathways explored at Cold Spring Harbor Laboratory. Additional studies by virology labs at University of Pennsylvania and Institut Pasteur demonstrated antiviral effects against Ebola virus, Dengue virus, and SARS‑CoV in assays modeled after protocols from National Institutes of Health.
Preclinical evaluation in rodent models at University of Michigan and nonhuman primate studies coordinated with NIH National Center for Advancing Translational Sciences suggested efficacy in models of acute leukemia and hormone‑resistant cancers analogous to trials run by cooperative groups like SWOG and EORTC. Pharmacokinetic characterization using methods from FDA guidance and conducted in facilities linked to GlaxoSmithKline identified challenges of bioavailability and first‑pass metabolism, prompting formulation research at AstraZeneca and academic groups at University of California, San Francisco. Combination strategies with agents developed at Roche and Bristol‑Myers Squibb have been explored to enhance therapeutic index.
Total synthesis campaigns by research groups at Harvard University, California Institute of Technology, University of Chicago, and Peking University established routes to rocaglamide, silvestrol, and simplified analogs; methods include cycloaddition, asymmetric catalysis, and cascade strategies pioneered by scientists associated with Nobel Prize‑winning techniques. Medicinal chemistry programs at Merck and academic collaborations have produced semisynthetic derivatives and prodrugs designed to improve solubility and selectivity, with structural optimization informed by SAR studies from labs at University of Texas Southwestern Medical Center.
Toxicology studies at contract research organizations partnering with National Toxicology Program revealed narrow therapeutic windows in some models, with hepatotoxicity and hematologic effects reported in preclinical assessments conducted by groups at Eli Lilly and university toxicology cores like those at University of North Carolina. Early‑phase clinical development efforts inspired by translational initiatives at NIH Clinical Center and coordinated networks such as Cancer Research UK have been cautious, emphasizing dose‑finding and biomarker development guided by standards from European Medicines Agency and International Council for Harmonisation. Continued research balances potential anticancer and antiviral benefits against safety profiles characterized in GLP studies.
Category:Natural products